IRIS Institutional Research Information System - OPENBS Open Archive UniBS

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.179
AS - Asia 4.175
EU - Europa 2.589
SA - Sud America 913
Continente sconosciuto - Info sul continente non disponibili 201
AF - Africa 107
OC - Oceania 8
Totale 14.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.986
SG - Singapore 1.676
CN - Cina 987
BR - Brasile 745
IT - Italia 732
HK - Hong Kong 515
DE - Germania 351
VN - Vietnam 315
FI - Finlandia 224
UA - Ucraina 221
FR - Francia 218
PL - Polonia 186
BD - Bangladesh 176
GB - Regno Unito 163
TR - Turchia 162
RU - Federazione Russa 158
IN - India 108
CA - Canada 101
IE - Irlanda 72
AR - Argentina 56
SE - Svezia 50
ZA - Sudafrica 48
MX - Messico 45
NL - Olanda 41
CZ - Repubblica Ceca 40
IQ - Iraq 39
JP - Giappone 37
ES - Italia 27
AT - Austria 26
EC - Ecuador 24
CO - Colombia 22
VE - Venezuela 19
BE - Belgio 17
ID - Indonesia 16
JO - Giordania 16
PY - Paraguay 14
PE - Perù 13
MA - Marocco 12
MY - Malesia 11
UZ - Uzbekistan 11
PH - Filippine 10
SA - Arabia Saudita 10
TH - Thailandia 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
JM - Giamaica 9
CR - Costa Rica 8
ET - Etiopia 8
IL - Israele 8
PK - Pakistan 8
PT - Portogallo 8
TN - Tunisia 8
AU - Australia 7
AZ - Azerbaigian 7
CL - Cile 7
GR - Grecia 7
KG - Kirghizistan 7
LT - Lituania 7
PA - Panama 7
UY - Uruguay 7
BO - Bolivia 6
DZ - Algeria 6
HN - Honduras 6
KE - Kenya 6
BG - Bulgaria 5
IR - Iran 5
LV - Lettonia 5
OM - Oman 5
PS - Palestinian Territory 5
LK - Sri Lanka 4
MD - Moldavia 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
CH - Svizzera 3
CI - Costa d'Avorio 3
GT - Guatemala 3
HU - Ungheria 3
NP - Nepal 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AL - Albania 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
HR - Croazia 2
IM - Isola di Man 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BZ - Belize 1
Totale 13.963
Salva come PNG Salva come JPEG
Città #
Singapore 905
Ashburn 655
Hong Kong 513
San Jose 480
Fairfield 377
Beijing 293
New York 268
The Dalles 227
Chandler 195
Woodbridge 194
Dallas 184
Los Angeles 176
Seattle 175
Warsaw 174
Jacksonville 162
Helsinki 160
Munich 160
Wilmington 148
Council Bluffs 143
Cambridge 138
Brescia 135
Houston 128
Lauterbourg 123
Ann Arbor 121
Istanbul 116
Princeton 116
Ho Chi Minh City 98
Columbus 90
Des Moines 79
São Paulo 79
Santa Clara 77
Hanoi 70
Dublin 69
San Francisco 69
Shanghai 68
Chicago 63
Boardman 61
Moscow 61
Buffalo 59
Redondo Beach 57
Orem 50
Milan 48
Turku 47
Romola 41
London 39
Rome 36
Tokyo 33
Johannesburg 32
Brooklyn 31
Brno 30
Montreal 30
Denver 29
Phoenix 28
Frankfurt am Main 27
Nuremberg 27
Atlanta 25
Toronto 24
Boston 22
Belo Horizonte 21
Charlotte 21
Rio de Janeiro 21
Nanjing 20
Pune 19
San Diego 19
Amsterdam 18
Chennai 18
Manchester 18
Stockholm 18
Brussels 17
Da Nang 17
Jinan 17
Amman 16
Haiphong 16
Guangzhou 15
Brasília 14
Tianjin 14
Baghdad 13
Dearborn 13
Kyiv 13
Mexico City 13
Paris 13
Barlassina 12
Biên Hòa 12
Curitiba 12
Florence 12
Lappeenranta 12
Mumbai 12
Naples 12
Poplar 12
Dhaka 11
Shenyang 11
Turin 11
Changsha 10
Genoa 10
Tashkent 10
Verona 10
Wroclaw 10
Ankara 9
Bologna 9
Bosio 9
Totale 8.655
Salva come PNG Salva come JPEG
Nome #
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 298
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 212
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 202
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 187
Advances in CMV Management: A Single Center Real-Life Experience 178
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 175
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 175
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 170
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 169
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 167
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 167
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 167
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 162
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 162
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 161
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 156
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 151
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 151
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 150
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 148
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 147
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 146
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 143
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 142
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 140
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 139
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 136
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 135
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 135
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 135
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 134
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 134
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 134
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 132
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 132
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 132
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 132
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 131
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 131
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 130
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 130
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 130
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 128
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 126
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 126
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 125
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 124
A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation 123
EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A RETROSPECTIVE MULTICENTRIC ANALYSIS ON 94 PATIENTS. 122
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 120
EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO) 118
PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT) 118
Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience 117
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 114
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 113
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 111
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 111
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 111
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party 110
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 110
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 109
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 109
Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis 106
Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit 106
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 105
Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message? 105
dsDNA from extracellular vesicles (EVs) in adult AML 103
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 102
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 102
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 100
Favourable/Intermediate ELN-Risk Acute Myeloid Leukemia to Transplant or Not to Transplant First-Line? 100
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 99
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 98
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 97
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 97
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) 95
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 90
Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood? 88
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience 84
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 84
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 81
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 80
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 79
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 77
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 77
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study 76
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: Possible role of MPL polymorphisms 76
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT 74
Long-term follow-up of essential thrombocythemia in young adults: Treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients 73
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 72
Splenectomy as a curative treatment for immune thrombocytopenia: A retrospective analysis of 233 patients with a minimum follow up of 10 years 71
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 71
A case report of acute myeloid leukemia and neurofibromatosis 1 70
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 67
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 65
Bleeding in essential thrombocythaemia: A retrospective analysis on 565 patients 65
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 65
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT 65
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study 64
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 63
Totale 12.025
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.317
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022478 0 0 18 42 18 45 27 49 30 87 33 129
2022/2023683 79 19 30 52 55 136 3 129 82 17 43 38
2023/20241.196 51 26 96 62 72 221 50 46 287 14 17 254
2024/20252.877 39 56 82 334 291 240 175 116 399 236 522 387
2025/20266.025 508 618 495 919 566 404 830 271 380 578 243 213
2026/2027730 206 361 163 0 0 0 0 0 0 0 0 0
Totale 14.172